Johnson & Johnson SEC Filings

A holder of JNJ common stock filed a notice of proposed sale of 100,000 shares under Rule 144. The shares are to be sold through J.P. Morgan Securities LLC on the NYSE, with an aggregate market value of $22,014,000 based on the figures in the notice. As context, the filing lists 2,409,295,102 JNJ common shares outstanding. The planned sale date is approximately 01/26/2026.

The 100,000 shares of common stock were acquired on 03/18/2025 via a transfer from Joaquin Duoto, who originally received the shares as compensation between 02/12/2021 and 02/13/2023. The form also includes the standard representation that the seller is not aware of any undisclosed material adverse information about the issuer’s current or prospective operations.

Johnson & Johnson filed a Form 8-K to share that it has issued a press release announcing its sales and earnings for the fourth quarter and full year ended December 28, 2025. The filing states that the press release is attached as Exhibit 99.1 and covers both quarterly and annual performance.

The company also attached unaudited comparative supplementary sales data and a condensed consolidated statement of earnings for the same periods as Exhibit 99.2. This 8-K centers on making these earnings materials publicly available rather than detailing the specific financial results within the form itself.

Johnson & Johnson, together with its subsidiary Johnson & Johnson Innovation – JJDC, Inc., reports beneficial ownership of 4,024,861 shares of CVRx, Inc. common stock, representing 15.4% of the class as of the measurement date. JJDC directly owns the shares, and Johnson & Johnson may be deemed to indirectly own them through its wholly owned subsidiary.

The ownership percentage is calculated against 26,210,109 CVRx common shares outstanding as of October 30, 2025, with the ownership position reported as of December 31, 2025. All voting and dispositive power over these shares is reported as shared rather than sole.

Johnson & Johnson, as a reporting person and director of CVRx, Inc., filed an amended Form 4 to correct an earlier insider transaction report. Through its wholly owned subsidiary Johnson & Johnson Innovation - JJDC, Inc., it sold 16,000 shares of CVRx common stock on 11/25/2025 at a weighted average price of $10.03, and 6,337 shares on 11/26/2025 at a weighted average price of $10.03. The shares on 11/25/2025 were sold in multiple trades between $10.00 and $10.22, and on 11/26/2025 between $10.00 and $10.23. After these sales, 4,024,861 CVRx shares were reported as indirectly beneficially owned by Johnson & Johnson through JJDC. The amendment states the 11/25/2025 sale was omitted from the original filing due to an administrative oversight.

Johnson & Johnson director reports deferred share units award

A Johnson & Johnson (JNJ) director reported receiving 185.533 Deferred Share Units (DSUs) on 12/09/2025 at a price of $202.12 per unit. After this transaction, the director beneficially owns 5,058.0682 DSUs in total, held directly.

The DSUs were acquired by deferring the director’s cash retainer under Johnson & Johnson’s Amended and Restated Deferred Fee Plan for Directors. These units will be settled in cash when the director’s board service ends, and each DSU represents the fair market value of one share of Johnson & Johnson common stock on the business day before settlement. The total includes dividend-equivalent rights that accrue on DSUs in line with the company’s quarterly dividend.

Johnson & Johnson director reports deferred share unit award

A Johnson & Johnson (JNJ) director reported receiving 247.378 Deferred Share Units (DSUs) on 12/09/2025 at a price of $202.12 per unit under the company’s Amended and Restated Deferred Fee Plan for Directors. After this transaction, the director beneficially owned 14,153.1187 DSUs in total.

The DSUs represent the fair market value of one share of Johnson & Johnson common stock and are to be settled in cash when the director’s service on the board ends. The holdings also include dividend equivalent rights that accrue on DSUs in line with the company’s quarterly dividend, keeping the director’s deferred compensation aligned with shareholder payouts.

Johnson & Johnson director Daniel E. Pinto reported a compensation-related equity transaction. On 12/09/2025, he acquired 154.611 Deferred Share Units (DSUs) under Johnson & Johnson’s Amended and Restated Deferred Fee Plan for Directors at a derivative security price of $202.12. Following this transaction, he beneficially owned 331.233 DSUs.

The DSUs represent deferred cash retainers and are to be settled in cash when his service as a director ends. Each DSU is tied to the fair market value of one share of Johnson & Johnson common stock on the business day before settlement. The reported balance also includes dividend equivalent rights accrued on DSUs he already held.

Johnson & Johnson director John Morikis reported buying company stock. On 11/26/2025, he acquired 1,250 shares of common stock at a price of $206.15 per share, coded as transaction type "P." After this purchase, he beneficially owned 1,848.51 shares, held directly. The Form 4 indicates the filing relates to one reporting person and shows no derivative securities transactions.

Johnson & Johnson filed a Form 4 reporting small open-market sales of CVRx, Inc. common stock held indirectly through its subsidiary Johnson & Johnson Innovation - JJDC, Inc. JJDC sold 500 CVRx shares on 11/21/2025 at a price of $10.00 per share and 2,200 shares on 11/24/2025 at a weighted average price of $10.06 per share. After these transactions, Johnson & Johnson, through JJDC, indirectly beneficially owned 4,047,198 CVRx common shares. The filing notes that the 11/24/2025 price reflects multiple trades between $10.00 and $10.10, and Johnson & Johnson undertakes to provide detailed trade breakdowns upon request.